January 26, 2017: Bragar Eagel & Squire, P.C., announce that the court has granted final approval of the settlement in In re Cornerstone Therapeutics Inc. Stockholder Litigation, Consolidated C.A. No. 8922-VCG, Court of Chancery of the State of Delaware. Plaintiffs brought this action alleging that Defendants breached their fiduciary duties by approving the acquisition of Cornerstone Therapeutics Inc. (“Cornerstone”) by Chiesi Farmaceutici S.p.A. at an unfair price of 9.50 per share. Pursuant to the settlement,, in return for releases and dismissal of the claims, Defendants will pay $17,881,555.20 for the benefit of the Class. This amount represents a $2.40 per share, or a 25.2% premium above the merger price. A copy of the settlement agreement and exhibits can be obtained through the Court’s website.
Attorney Advertising. Prior results do not guarantee a similar outcome.